These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 14613353)

  • 21. A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough.
    Shanes JG
    Curr Atheroscler Rep; 2012 Feb; 14(1):33-40. PubMed ID: 22109348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid sequestrants and diabetes: introduction and overview to the supplement.
    Jialal I
    Metab Syndr Relat Disord; 2010 Dec; 8 Suppl 1(Suppl 1):S1-2. PubMed ID: 20973745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.
    Marrs JC
    Drugs Aging; 2012 May; 29(5):e1-e12. PubMed ID: 22530704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colesevelam: a review of its use in hypercholesterolemia.
    Robinson DM; Keating GM
    Am J Cardiovasc Drugs; 2007; 7(6):453-65. PubMed ID: 18076213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel therapeutic approach.
    Denke MA
    J Manag Care Pharm; 2003; 9(1 Suppl):13-6. PubMed ID: 14613354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colesevelam hydrochloride in the management of dyslipidemia.
    Armani A; Toth PP
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
    Knapp HH; Schrott H; Ma P; Knopp R; Chin B; Gaziano JM; Donovan JM; Burke SK; Davidson MH
    Am J Med; 2001 Apr; 110(5):352-60. PubMed ID: 11286949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL
    Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
    Perry CM
    Paediatr Drugs; 2010 Apr; 12(2):133-40. PubMed ID: 20218749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel therapeutic approach to dyslipidemia.
    Clearfield MB
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S16-20. PubMed ID: 12572626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus.
    Goldberg RB; Rosenson RS; Hernandez-Triana E; Misir S; Jones MR
    J Clin Lipidol; 2012; 6(4):318-24. PubMed ID: 22836068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rationale for combination therapy.
    Rosenson RS
    Am J Cardiol; 2002 Nov; 90(10B):2K-7K. PubMed ID: 12467935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia.
    Zema MJ
    Am J Ther; 2005; 12(4):306-10. PubMed ID: 16041193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.